Company profile for Aardvark Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Our lead product, ARD-101, is a first-in-class oral composition that is gut restricted, y...
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Our lead product, ARD-101, is a first-in-class oral composition that is gut restricted, yet conveys systemic effects via activation of gut peptide hormone secretion. Preclinical data demonstrate safety as well as efficacy in a number of metabolic and inflammatory disease models.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
12707 High Bluff Drive, Suite 200 San Diego, CA 92130-2035
Telephone
Telephone
+1 616-3370-224
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

euroPLX 90 Lisbon

Not Confirmed

envelop Contact Supplier

euroPLX 90 Lisbon

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/02/27/3246791/0/en/Aardvark-Therapeutics-Announces-Voluntary-Pause-of-Phase-3-HERO-Trial-in-Prader-Willi-Syndrome.html

GLOBENEWSWIRE
27 Feb 2026

https://www.globenewswire.com/news-release/2026/02/13/3238066/0/en/Aardvark-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
13 Feb 2026

https://www.globenewswire.com/news-release/2026/02/12/3237145/0/en/Aardvark-Therapeutics-Announces-Leadership-Appointments.html

GLOBENEWSWIRE
12 Feb 2026

https://www.globenewswire.com/news-release/2026/02/10/3235262/0/en/Aardvark-Therapeutics-Announces-FDA-Submission-and-IRB-Approval-of-Amended-Trial-Protocol-for-Lead-Candidate-ARD-101-Expanding-Eligibility-in-Phase-3-Study-of-Prader-Willi-Syndrome.html

GLOBENEWSWIRE
10 Feb 2026

https://www.globenewswire.com/news-release/2025/12/10/3203500/0/en/Aardvark-Therapeutics-Announces-First-Patient-Dosed-in-Australia-in-HERO-Phase-3-Trial-for-Prader-Willi-Syndrome.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/11/25/3194727/0/en/Aardvark-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-December.html

GLOBENEWSWIRE
25 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty